ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Our case suggests that asciminib, in addition to showing promising outcomes in CML patients with the major <i>BCR::ABL1</i> transcript, is an effective treatment option for CML patients with the e19a2 micro <i>BCR::ABL1</i> transcript.